VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

GU Cancers 2023 | FORMULA-509 rationale + trial design: the addition of AAP + apa post-radical prostatectomy

Paul L. Nguyen, MD, Dana-Farber Cancer Institute, Boston, MA, shares the rational and trial design of the Phase II randomized FORMULA-509 (NCT03141671) trial assessing post-operative salvage radiotherapy and 6 months of GnRH agonist with or without abiraterone acetate/prednisone and apalutamide post-radical prostatectomy in patients with a rising PSA after radical prostatectomy. The standard treatment for patients with prostate cancer is usually salvage radiation with 6 months of androgen deprivation therapy (ADT). The trial assessed whether adding 6 months of apalutamide and abiraterone could improve outcomes compared to the standard of 6 months of bicalutamide with 6 months of ADT. Patients had PSA≥0.1 post-radical prostatectomy and one or more unfavorable features (Gleason 8-10, PSA more than 0.5 pT3/T4, pN1 or radiographic N1, PSA doubling time less than 10 months, negative margins, persistent PSA, gross local/regional disease, or Decipher High Risk) and were stratified by PSA level and node positivity. This interview took place at the ASCO GU Cancers Symposium 2023 in San Francisco, CA.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter